×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: PPH

Broker News

PPH – UBS rates the stock as Neutral

November 5, 2020 - by Broker News

UBS observes a strong first half for Pushpay Holdings with beats on revenue, gross margins and operating income. With no growth in the total number of churches, the slowdown in the front book was greater than the broker expected.

Read More
Broker News

PPH – Credit Suisse rates the stock as Outperform

September 23, 2020 - by Broker News

Credit Suisse expects FY21 to be “remarkable” with a shift to digital donations accelerating significantly and the platform becoming indispensable to clients.

Read More
Shares

The Business Models Holding Up In The Rout

April 1, 2020April 3, 2020 - by Tim Boreham

Beyond the dismal parade of ASX-listed victims ensuing from the corona crisis, a low-profile cluster of stocks is benefiting from the mayhem.

Read More
Broker News

PPH – UBS rates the stock as Buy

December 20, 2019 - by Broker News

UBS observes the company has outperformed the market by 20% over the last month because of improved operating leverage, double-digit back book growth and the acquisition of Church Community Builder.

Read More
Shares

Pushpay Holdings Expands Horizons

December 18, 2019December 18, 2019 - by Eva Brocklehurst

Brokers anticipate the acquisition of Church Community Builder by Pushpay Holdings will provide additional value and stabilise front book growth.

Read More
  • US Political Protests, Inflation and Rising Bond Yields
  • Huge Week for Netflix as Shares Touch Record High
  • Is it Time to Buy Airports and Toll Road Companies?
  • Little to Cheer About as Xmas Retail Spending Slumps
  • Evening Report: ASX eases into the weekend
  • CCL Slightly Exceeds Expectations but Indonesia Still a Worry
  • COVID Still Driving FPH Revenue as Earnings Surge
  • RMD – UBS rates the stock as Buy

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Star.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Heart.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.